Valneva SE announced this week that the first participant has been vaccinated in the Phase 2 clinical trial evaluating the safety and Immunogenicity in children of two different dose levels of Valneva’s single-shot chikungunya vaccine.
The Company reported positive pivotal Phase 3 data in adolescents two months ago confirming the immunogenicity and safety profile observed in adults.
While there is currently no approved chikungunya vaccine for children, Valneva does offer a chikungunya vaccine for adults 18 years and older, targeting individuals who are increased risk of exposure.
Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus (CHIKV), a Togaviridae virus, transmitted by Aedes mosquitoes. Infection leads to symptomatic disease in up to 97% of humans after four to seven days following the mosquito bite.


Source: 


Source: 

Source: 
You must be logged in to post a comment.